The company filed a provisional patent application with the United States Patent and Trademark Office (USPTO) as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat central nervous system disorders.
This patent is an addition to Clearmind's robust intellectual property portfolio that includes patents for MEAI as a binge behavior regulator, as an alcoholic beverage substitute and others.
The patent application refers to novel proprietary combinations of MEAI and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™. It demonstrates Clearmind’s corporate mission to broaden the therapeutic psychedelic toolbox for patients with mental health disorders who await treatments with increased efficacy and safety while reducing cost.
Clearmind has a broad IP footprint in the psychedelic space with 24 patents in 14 patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India. The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's PEA compound for treating alcohol use disorder, cocaine addiction, and obesity and its related metabolic disorders.
Recent CMND News
- Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product • GlobeNewswire Inc. • 07/19/2024 11:55:00 AM
- Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism • GlobeNewswire Inc. • 07/16/2024 01:02:00 PM
- SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss • GlobeNewswire Inc. • 07/16/2024 10:03:00 AM
- Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss • GlobeNewswire Inc. • 07/16/2024 10:03:00 AM
- Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference • GlobeNewswire Inc. • 07/12/2024 12:02:00 PM
- Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment • GlobeNewswire Inc. • 06/28/2024 11:55:00 AM
- Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment • GlobeNewswire Inc. • 06/20/2024 11:57:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/13/2024 08:01:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/13/2024 08:01:28 PM
- Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink • GlobeNewswire Inc. • 06/11/2024 11:44:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/10/2024 08:01:10 PM
- Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product • GlobeNewswire Inc. • 05/10/2024 12:24:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2024 08:01:25 PM
- Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment • GlobeNewswire Inc. • 05/07/2024 11:46:00 AM
- Clearmind Applies to Cease Being a Reporting Issuer in Canada • GlobeNewswire Inc. • 04/30/2024 08:15:00 PM
- Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders • GlobeNewswire Inc. • 04/17/2024 11:49:00 AM
- Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders • GlobeNewswire Inc. • 04/10/2024 11:17:00 AM
- Clearmind Medicine CEO Issues Letter to Shareholders • GlobeNewswire Inc. • 04/09/2024 12:07:00 PM
- Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China • GlobeNewswire Inc. • 03/19/2024 11:55:00 AM
- Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial • GlobeNewswire Inc. • 03/13/2024 12:14:00 PM
- Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange • GlobeNewswire Inc. • 03/13/2024 11:30:00 AM
- Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder • GlobeNewswire Inc. • 02/23/2024 12:06:00 PM
- Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM